Lesson plan
IAG933
IAG933 is an investigational new drug that is being evaluated for the treatment of cancer. IAG933 is a small molecule inhibitor developed by Novartis Pharmaceuticals to directly disrupt the YAP/TAZ-TEAD protein-protein interaction, a critical mediator of oncogenic signaling in the Hippo pathway. This drug has demonstrated potent and selective inhibition of all four TEAD paralogs, resulting in YAP eviction from chromatin and reduced Hippo-mediated transcription. As of 2024, IAG933 is undergoing Phase I clinical trials to evaluate its safety, tolerability, and preliminary anti-tumor activity in patients with advanced mesothelioma and other solid tumors harboring specific molecular alterations in the Hippo pathway. As of October 2025, Novartis indicated enrollment in the phase 1 clinical trial had been halted due to lack of efficacy.
Article summary
IAG933 is an investigational new drug that is being evaluated for the treatment of cancer. IAG933 is a small molecule inhibitor developed by Novartis Pharmaceuticals to directly disrupt the YAP/TAZ-TEAD protein-protein interaction, a critical mediator of oncogenic signaling in the Hippo pathway. This drug has demonstrated potent and selective inhibition of all four TEAD paralogs, resulting in YAP eviction from chromatin and reduced Hippo-mediated transcription. As of 2024, IAG933 is undergoing Phase I clinical trials to evaluate its safety, tolerability, and preliminary anti-tumor activity in patients with advanced mesothelioma and other solid tumors harboring specific molecular alterations in the Hippo pathway. As of October 2025, Novartis indicated enrollment in the phase 1 clinical trial had been halted due to lack of efficacy.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.